Jonathan Hilts, DO
Rheumatology · Bismarck, NDNPI 1093061988
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,624 of the $1,823 with a category attached, or 89.1%. 31 manufacturers reported payments, led by Johnson & Johnson at 29.0% of the total.
Across 78 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$529
- AstraZeneca$173
- Amgen$130
- Actelion Pharmaceuticals US, Inc.$123
- Biogen$87
- Aurinia Pharma U.S., Inc.$84
- plus $696 from 25 others
What the payments were for
- Food & beverage$1,62489%
- Education$19911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 13 | $529 |
| AstraZeneca(2 entities) | 12 | $173 |
| Amgen(2 entities) | 7 | $130 |
| Actelion Pharmaceuticals US, Inc. | 2 | $123 |
| Biogen | 5 | $87 |
| Aurinia Pharma U.S., Inc. | 1 | $84 |
| AbbVie | 3 | $76 |
| Grifols USA, LLC | 5 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| UCB, Inc. | 2 | $41 |
| Boston Scientific | 1 | $39 |
| Lilly USA, LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Eisai Inc. | 1 | $31 |
| Melinta Therapeutics, LLC | 2 | $30 |
| Sandoz | 1 | $29 |
| Pfizer | 2 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| Merz North America, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Amylyx Pharmaceuticals, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $14 |
| Radius Health, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 24 | $216,209 |
| EnbrelEtanercept | 17 | $125,579 |
| Humira(Cf) PenAdalimumab | 12 | $104,488 |
| BenlystaBelimumab | 12 | $57,204 |
| OtezlaApremilast | 11 | $52,360 |
| Hydroxychloroquine Sulfate | 328 | $20,937 |
| MethotrexateMethotrexate Sodium | 447 | $19,497 |
| Leflunomide | 104 | $7,581 |
| Mycophenolate Mofetil | 56 | $4,902 |
| Duloxetine Hcl | 75 | $4,062 |
| Sulfasalazine | 75 | $2,188 |
| Prednisone | 140 | $2,107 |
| Celecoxib | 22 | $670 |
| Alendronate Sodium | 47 | $555 |
| Gabapentin | 30 | $530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $130 | $177,93928 claims |
| GSKBenlysta | $19 | $57,20412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other rheumatology in Bismarck
- Christian DequetBismarck$8K
- Nowarat SongsiridejBismarck$665
- Yuri NakasatoFargo$6K
- Esperanza ArgenzianoGrand Forks$1K
- Mosaab MohamedenFargo$793
- Viktorija OverieneFargo$636
- Erdal DiriMinot$291
- Meghan ScheibeFargo$149
- Lorna CampbellFargo$45
- Mahfooz PeshimamFargo$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.